Kalvista Pharmaceuticals Inc.

06/22/2026 | Press release | Distributed by Public on 06/22/2026 07:00

Termination Notice (Form 15-12G)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 15


CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File No. 001-36830


KalVista Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)


200 Crossing Boulevard
Framingham, Massachusetts 01702
(857) 999-0075
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Common Stock, par value $0.001 per share
(Title of each class of securities covered by this Form)

None
(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)


Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)
☒
Rule 12g-4(a)(2)
☐
Rule 12h-3(b)(1)(i)
☒
Rule 12h-3(b)(1)(ii)
☐
Rule 15d-6
☐
Rule 15d-22(b)
☐

Approximate number of holders of record as of the certification or notice date: One holder.

Pursuant to the requirements of the Securities Exchange Act of 1934, KalVista Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

KalVista Pharmaceuticals, Inc.
Date:
June 22, 2026
By:
/s/ John Hess
Name:
John Hess
Title:
Chairman of the Board; President; General Manager


Kalvista Pharmaceuticals Inc. published this content on June 22, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 22, 2026 at 13:00 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]